Cargando…
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint
Autores principales: | Ravinetto, Raffaella, De Weggheleire, Anja, Dorlo, Thomas P.C., Francque, Sven, Sokkab, An, Pouget, Corinne, Meessen, Bruno, Tabernero, Patricia, Newton, Paul N., Lynen, Lut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244681/ https://www.ncbi.nlm.nih.gov/pubmed/27671365 http://dx.doi.org/10.1111/tmi.12784 |
Ejemplares similares
-
Development of a risk score to guide targeted hepatitis C testing among human immunodeficiency virus patients in Cambodia
por: De Weggheleire, Anja, et al.
Publicado: (2021) -
Quality assurance systems of pharmaceutical distributors in low-income and middle-income countries: weaknesses and ways forward
por: Nebot Giralt, Ariadna, et al.
Publicado: (2020) -
Challenges to Differentiate Hepatitis C Genotype 1 and 6: Results from A Field-Study in Cambodia
por: De Weggheleire, Anja, et al.
Publicado: (2020) -
Pharmaceutical quality assurance of local private distributors: a secondary analysis in 13 low-income and middle-income countries
por: Van Assche, Kerlijn, et al.
Publicado: (2018) -
A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening
por: De Weggheleire, Anja, et al.
Publicado: (2017)